Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of NUFORMIX PLC
No Price
Closing Price XLON 29.04.2026:
0,17 GBX
29.04.2026 14:41
Current Prices from NUFORMIX PLC
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
London
NFX.L
GBX
29.04.2026 14:41
0,17 GBX
-0,01 GBX
-6,49 %
Share Float & Liquidity
Free Float90,81 %
Shares Float1,92 B
Shares Outstanding2,11 B
Company Profile for NUFORMIX PLC Share
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
